Hotline: 1800 102 2007
Hotline: 1800 102 2007
Feb, 10 2017

​Aurobindo acquires four products TL Biopharmaceuticals AG

Aurobindo is preparing to take its lead molecule from this transaction, a Bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab is an anti-antiogenesis drug used in treating multiple cancers including metastatic colon or rectal cancer, non-squa

​Aurobindo acquires four products TL Biopharmaceuticals AG

Aurobindo Pharma Limited has announced that it has acquired four cell culture derived biosimilar products from TL Biopharmaceutical AG of Switzerland. The company, however, did not disclose the deal value.

As part of the agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialise and market these products globally.

The branded market size of these four biosimilars, three of them monoclonal antibodies in oncology is very promising, the company said. Regulatory filing for these products is intended in the period 2020-22.

Aurobindo is preparing to take its lead molecule from this transaction, a Bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab is an anti-antiogenesis drug used in treating multiple cancers including metastatic colon or rectal cancer, non-squamous and non-small cell lung cancers.

The transaction is a strategic investment for future growth and will position Aurobindo as a strong player in the rapidly evolving biosimilars landscape, according to the company.

Building on these first four products licensed from TL, Aurobindo is expanding its diverse portfolio of eight more next wave of biosimilars ensuring a strong and diverse products pipeline, it said.

Aurobindo has set up a fully functional R&D center for biologics development and is also establishing a state-of-the-art manufacturing facility in Hyderabad and is expected to be ready by the second quarter of the financial year 2017-18.

N Govindarajan, Managing director, Aurubindo, said in a statement, "We are impressed with the TL product development as these products are developed to the highest standards of biosimilarity. This acquisition is in line with our strategy of investing in complex products and is an important first step towards establishing Aurobindo's global biosimilar portfolio."

sharebtn
Comment
user
email
mobile
address
star
Related opportunities
  • Beauty Salons
    About Us: Cut & style is one of the finest and..
    Locations looking for expansion New Delhi
    Establishment year 2000
    Franchising Launch Date 2018
    Investment size Rs. 30lac - 50lac
    Space required 800
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater DELHI New Delhi
  • Tea And Coffee Chain
    About Us: SD Café is truly an all-day-dining cafe chain, a..
    Locations looking for expansion Maharashtra
    Establishment year 2012
    Franchising Launch Date 2019
    Investment size Rs. 10lac - 20lac
    Space required 250
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Pune Maharashtra
  • Preschools
    About Us: An ISO 9001-2015 certified Preschool Brand, operating in FOFO..
    Locations looking for expansion Maharashtra
    Establishment year 2016
    Franchising Launch Date 2017
    Investment size Rs. 10lac - 20lac
    Space required 1500
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater ahmedabad Maharashtra
  • Clinics & Nursing Homes
    Diagnopein  is the Fastest Growing Chain Of Diagnostics & Dental..
    Locations looking for expansion Maharashtra
    Establishment year 2018
    Franchising Launch Date 2019
    Investment size Rs. 20lac - 30lac
    Space required 280
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Pune Maharashtra
Insta-Subscribe to
Entrepreneur
Magazine
sme-80x109
For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you
email
mobile
OR Click here to Subscribe Online
Daily Updates
Submit your email address to receive the latest updates on news & host of opportunities